PIk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6635-6647

  Zhang, Zhe ^a,b   Hou, Xianzeng ^a,c   Shao, Chen ^a   Li, Junjie ^d   Cheng, Ji Xin ^d   Kuang, Shihuan ^a   Ahmad, Nihal ^e   Ratliff, Timothy ^f   Liu, Xiaoqi ^a,f  

^a PURDUE UNIVERSITY   (United States)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d PURDUE UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ABIRATERONE; ANTIANDROGEN; CHOLESTEROL ESTER; ENZALUTAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN; CELL CYCLE PROTEIN; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TARGET OF RAPAMYCIN KINASE;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL FRACTIONATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAMAN SPECTROMETRY; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOR SERINE-THREONINE KINASES;

EID: 84918554672     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1916     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
3. Saad F. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol 2013;5:201-10.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.
5. Rathkopf DE, Smith MR, De Bono JS, Logothetis CJ, Shore ND, De Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; pii: S0302-2838 (14) 00185-7.
6. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med 2013;368:1458-9.
7. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
8. Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTENloss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 2014;19:393-406.
9. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002;110:489-500.
10. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011;146:408-20.
11. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012;10:133-42.
12. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 2011;96:430-7.
13. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60.
14. Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, et al. Pololike kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem 2011;286:35795-800.
15. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012;72:527-36.
16. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46.
17. Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol 2002;2:1509-20.
18. Lin DC, Zhang Y, Pan QJ, Yang H, Shi ZZ, Xie ZH, Wang BS, et al. PLK1 Is transcriptionally activated by NF-kappaB during cell detachment and enhances anoikis resistance through inhibiting beta-catenin degradation in esophageal squamous cell carcinoma. Clin Cancer Res 2011;17:4285-95.
19. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141-51.
20. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 2010;29:3554-65.
21. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, et al. Castration resistance of prostate cancer cells caused by castrationinduced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010;29:237-50.
22. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castrationresistant prostate cancer. Cancer Res 2012;72:3457-62.
23. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
24. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
25. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, compound 30, suppresses castrationresistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013;12:567-76.
26. Yue S, Cardenas-Mora JM, Chaboub LS, Lelievre SA, Cheng JX. Label-free analysis of breast tissue polarity by Raman imaging of lipid phase. Biophys J 2012;102:1215-23.
27. Shiota M, Yokomizo A, Naito S. Oxidative stress and androgen receptor signaling in the development and progression of castrationresistant prostate cancer. Free Radic Biol Med 2011;51:1320-8.
28. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.
29. Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012;19:S22-31.
30. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD (P) H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003;163:2513-22.
31. Qin S, Chock PB. Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt. Biochemistry 2003;42:2995-3003.
32. Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. J Biol Chem 2013;288:5463-74.
33. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 2008;283:6209-21.
34. Liu XS, Li H, Song B, Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation duringG2 checkpoint recovery. EMBO Rep 2010;11:626-32.
35. Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, et al. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 2009;284:18588-92.
36. Li H, Liu XS, Yang X, Wang Y, Turner JR, Liu X. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochoremicrotubule attachments. Embo J 2010;29:2953-65.
37. Li H, Liu XS, Yang X, Song B, Wang Y, Liu X. Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci US A 2010;107:14633-8.
38. Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, et al. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 2013;73:1352-63.
39. Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, et al. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2013;12:58-68.
40. Song B, Liu XS, Davis K, Liu X. Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol 2011;31:4844-56.
41. Wu ZQ, Liu X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci US A 2008;105:1919-24.
42. Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, et al. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol 2014;34:3642-61.
43. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL. Androgenic biomarker prof | ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate 2014;74:722-31.